Review summary
Teaching objective: Localized prostate cancer found by a rising PSA in a fit man of 82, on the NCCN prostate guideline, the AUA/ASTRO 1997 localized prostate cancer guideline, and the CMID prostate cancer monograph: risk grouping and staging (unfavorable intermediate risk, with PSMA PET); shared decision-making among observation, radiotherapy with short-term androgen deprivation, and surgery, with life expectancy and an earlier prostate operation weighed; six months of androgen deprivation with radiotherapy, and the monitoring it needs (testosterone, bone density and vitamin D, glucose and lipids, blood pressure, hot flashes, mood, and cognition); urinary and bowel effects of radiotherapy; and PSA surveillance after radiotherapy with the Phoenix definition of recurrence. His doctors' public account, a slight PSA rise on monitoring, a biopsy, hormone therapy, and a seven-week course of curative radiotherapy, frames the episode.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| 18 July 1918 | Born in Mvezo, Eastern Cape. | CLM-0001 |
| 12 June 1964 | Sentenced to life imprisonment after the Rivonia Trial. | CLM-0002 |
| 1985 | Prostate surgery for an enlarged gland while imprisoned. | CLM-0003 |
| 12 August 1988 | Taken to hospital and diagnosed with tuberculosis. | CLM-0004 |
| 11 February 1990 | Released from Victor Verster Prison. | CLM-0002 |
| 10 May 1994 | Inaugurated as president of South Africa. | CLM-0009 |
| November 2000 | A raised PSA level is found on routine monitoring; a later biopsy shows microscopic prostate cancer. | CLM-0005 |
| July 24, 2001 | Diagnosis announced; a seven-week course of curative radiotherapy begins after hormonal treatment. | CLM-0006 |
| August 2001 | His office announces that radiation treatment will continue after a review of the options. | CLM-0007 |
| 2002 | Announces that his doctors have cleared him of prostate cancer. | CLM-0008 |
| 5 December 2013 | Died at his home in Johannesburg. | CLM-0010 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Nelson Rolihlahla Mandela was born in Mvezo, in the Eastern Cape, on 18 July 1918. | confirmed | Biography of Nelson Mandela supports |
| D | Mandela was convicted with seven co-accused in the Rivonia Trial on 11 June 1964 and sentenced to life imprisonment the next day. He was held on Robben Island, moved to Pollsmoor Prison on 31 March 1982 and to Victor Verster Prison near Paarl on 7 December 1988, and was released from Victor Verster on 11 February 1990. | confirmed | Biography of Nelson Mandela supports |
| D | In 1985 Mandela had prostate surgery while imprisoned. His urologist said in July 2001 that the gland had been enlarged and was causing a urinary blockage, and that part of it was removed. An operation for benign prostatic enlargement long before the cancer; the type of operation was not made public. Reports differ on the year and on how much of the gland was removed. |
confirmed | Biography of Nelson Mandela supports Mandela's prostate cancer not terminal, doctor says supports Early prostate cancer is curable (archived copy) context |
| D | Mandela was taken to hospital on 12 August 1988 and diagnosed with tuberculosis; public reports describe it as early tuberculosis, treated at the Constantiaberg Medi-clinic, after which he was moved to Victor Verster Prison. Pulmonary tuberculosis treated in the past; recorded as personal history. |
confirmed | Biography of Nelson Mandela supports Illnesses Madiba has suffered supports |
| D | His doctors said publicly in 2001 that he had been monitored regularly with the prostate-specific antigen (PSA) test, that a slight rise in the PSA led to a biopsy of the prostate, and that the biopsy confirmed microscopic cancer within the gland. News reports said the raised blood level was first found in November 2000. A PSA rise found on monitoring, with biopsy-proven localized prostate cancer. No PSA value, Gleason score, or stage was made public. |
confirmed | Early prostate cancer is curable (archived copy) supports Former South African President Nelson Mandela diagnosed with prostate cancer (Associated Press) supports Mandela begins radiation therapy supports |
| D | His spokeswoman said in July 2001 that the cancer was not of a high grade and should not shorten his life span. He received hormonal treatment (anti-androgens) for a while and then began a seven-week course of radiotherapy with curative intent, limited to the prostate, on July 24, 2001; no surgery or chemotherapy was needed. His urologist called it a very early cancer that should be cured. Localized, not high-grade prostate cancer treated with hormone therapy and curative radiotherapy, as his doctors and spokeswoman described it. |
confirmed | Early prostate cancer is curable (archived copy) supports Former South African President Nelson Mandela diagnosed with prostate cancer (Associated Press) supports Mandela begins radiation therapy supports Mandela's prostate cancer not terminal, doctor says supports |
| D | In August 2001 his office said he would continue radiation treatment after a review of the options by two physicians, a radiotherapist, and five urologists, who considered the size and grade of the tumour, the radiological tests, and his response to hormonal treatment; his office said his general health remained good. The treatment decision as his office announced it. |
confirmed | Mandela to continue radiation treatment supports |
| D | In 2002 Mandela announced that his doctors had cleared him of prostate cancer. Recorded as he announced it; no later result was made public and none is used. |
confirmed | Illnesses Madiba has suffered supports |
| D | Mandela was inaugurated as South Africa's first democratically elected president on 10 May 1994 and stepped down in 1999 after one term. | confirmed | Biography of Nelson Mandela supports |
| D | Mandela died at his home in Johannesburg on 5 December 2013. Recorded as a fact; no detail of his last years is used. |
confirmed | Biography of Nelson Mandela supports Nelson Mandela timeline 2000-2014 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed | both_with_link | CLM-0005, CLM-0006, CLM-0007 |
| S | Hormone-sensitive prostate cancer | active | confirmed | active | CLM-0005, CLM-0006 |
| S | Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition | active | confirmed | active | CLM-0005, CLM-0006 |
| S | History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed | historical | CLM-0004 |
| S | Personal history of external beam radiotherapy to the prostate | active | confirmed | active | CLM-0005, CLM-0006 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2001-03-10 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 6.4 ng/mL (high) Reference <=4 ng/mL |
http://loinc.org · 2857-1 |
| S | 2001-03-10 | Testosterone [Mass/volume] in Serum or Plasma | 412 ng/dL Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation |
http://loinc.org · 2986-8 |
| S | 2001-03-10 | Hemoglobin [Mass/volume] in Blood | 14.1 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2001-03-10 | Leukocytes [#/volume] in Blood by Automated count | 5.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2001-03-10 | Platelets [#/volume] in Blood by Automated count | 226 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2001-03-10 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2001-03-10 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2001-03-10 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2001-03-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2001-03-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M | 69 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2001-03-10 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2001-03-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2001-03-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 74 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2001-03-10 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2001-03-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2001-03-10 | Cholesterol [Mass/volume] in Serum or Plasma | 184 mg/dL Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2001-03-10 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2001-03-10 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2001-03-10 | Triglyceride [Mass/volume] in Serum or Plasma | 98 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2001-03-10 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 26 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2001-03-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2001-03-10 | International Prostate Symptom Score [IPSS] | 7 | http://loinc.org · 80976-4 |
| S | 2001-04-14 | DXA Femur [T-score] Bone density | -1.4 (low) Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis |
http://loinc.org · 38263-0 |
| S | 2001-04-14 | DXA Lumbar spine [T-score] Bone density | -0.6 Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis |
http://loinc.org · 38267-1 |
| S | 2001-04-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2001-07-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.9 ng/mL Reference <=4 ng/mL |
http://loinc.org · 2857-1 |
| S | 2001-07-14 | Testosterone [Mass/volume] in Serum or Plasma | 18 ng/dL (low) Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation |
http://loinc.org · 2986-8 |
| S | 2001-07-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2001-07-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2001-10-27 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.4 ng/mL Reference <=4 ng/mL |
http://loinc.org · 2857-1 |
| S | 2001-10-27 | Testosterone [Mass/volume] in Serum or Plasma | 38 ng/dL (low) Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation |
http://loinc.org · 2986-8 |
| S | 2001-10-27 | International Prostate Symptom Score [IPSS] | 12 | http://loinc.org · 80976-4 |
| S | 2001-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2001-06-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2001-06-09 | Total score [Mini-Cog] | 5 | http://loinc.org · 72233-0 |
| S | 2001-06-09 | Total score [AUDIT-C] | 0 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2001-03-10 | Body height | 183 cm | 8302-2 | S |
| 2001-03-10 | Body weight | 80.2 kg | 29463-7 | S |
| 2001-03-10 | Body mass index (BMI) [Ratio] | 23.9 kg/m2 | 39156-5 | S |
| 2001-03-10 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2001-03-10 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2001-03-10 | Heart rate | 68 /min | 8867-4 | S |
| 2001-03-10 | Respiratory rate | 14 /min | 9279-1 | S |
| 2001-03-10 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2001-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2001-04-14 | Body height | 183 cm | 8302-2 | S |
| 2001-04-14 | Body weight | 80.4 kg | 29463-7 | S |
| 2001-04-14 | Body mass index (BMI) [Ratio] | 24 kg/m2 | 39156-5 | S |
| 2001-04-14 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 2001-04-14 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2001-04-14 | Heart rate | 66 /min | 8867-4 | S |
| 2001-04-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 2001-04-14 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2001-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2001-07-14 | Body height | 183 cm | 8302-2 | S |
| 2001-07-14 | Body weight | 81.6 kg | 29463-7 | S |
| 2001-07-14 | Body mass index (BMI) [Ratio] | 24.4 kg/m2 | 39156-5 | S |
| 2001-07-14 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 2001-07-14 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2001-07-14 | Heart rate | 70 /min | 8867-4 | S |
| 2001-07-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 2001-07-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2001-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2001-10-27 | Body height | 183 cm | 8302-2 | S |
| 2001-10-27 | Body weight | 81.4 kg | 29463-7 | S |
| 2001-10-27 | Body mass index (BMI) [Ratio] | 24.3 kg/m2 | 39156-5 | S |
| 2001-10-27 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2001-10-27 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2001-10-27 | Heart rate | 68 /min | 8867-4 | S |
| 2001-10-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 2001-10-27 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2001-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2001-06-09 | Body height | 183 cm | 8302-2 | S |
| 2001-06-09 | Body weight | 81 kg | 29463-7 | S |
| 2001-06-09 | Body mass index (BMI) [Ratio] | 24.2 kg/m2 | 39156-5 | S |
| 2001-06-09 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2001-06-09 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2001-06-09 | Heart rate | 68 /min | 8867-4 | S |
| 2001-06-09 | Respiratory rate | 14 /min | 9279-1 | S |
| 2001-06-09 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2001-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Occupation: retired from public office; works with his foundation, speaks, and travels
- S Never smoker; no alcohol use reported; walks every morning
- S Lives in his own home with family; independent; has a driver
- S Supports: family, close friends, and a personal assistant who manages his schedule
Functional status
- S Independent in all activities and instrumental activities of daily living
- S Walks 30 to 45 minutes most mornings
Mental status
- S Alert, warm, and composed; asks direct questions and wants to weigh the treatment options himself
- S Mood good; PHQ-9 minimal at the first visit
Allergies and medications
Allergies
- S No known allergy
Medications
- S Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide
- S Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapy
- S Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily
- S Tamsulosin 0.4 mg oral capsule, one capsule by mouth once daily after the evening meal, for urinary frequency during radiotherapy
Procedures and immunizations
Procedures
- S Multiparametric MRI of the prostate: gland volume 28 mL with a resection defect from the earlier operation; 9 mm PI-RADS 4 lesion in the left peripheral zone at the mid-gland; no extraprostatic extension, seminal vesicle invasion, or enlarged pelvic nodes
- S MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+3 (Grade Group 3) in 1 of 2 targeted cores (30 percent of the core) and in 2 of 12 systematic cores (Gleason 3+4, 10 and 15 percent); 3 of 14 cores in all; no perineural invasion
- S Gallium-68 PSMA PET/CT for staging: uptake only in the left peripheral zone of the prostate; no nodal, bone, or visceral disease (N0 M0)
- S Transperineal insertion of three gold fiducial markers into the prostate for image guidance, with planning CT and MRI
- S Image-guided intensity-modulated radiotherapy to the prostate and proximal seminal vesicles, 74 Gy in 37 daily fractions over about seven and a half weeks, with curative intent; no pelvic nodal radiation
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2000-10-21: High-dose influenza vaccine, last season
- S 1994-05-14: Tdap vaccine
- S 2001-10-27: High-dose influenza vaccine, this season
- S 2001-06-09: Pneumococcal conjugate vaccine PCV20
- S 2001-06-09: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1985: Operation on the prostate for an enlarged gland causing urinary blockage, with part of the gland removed (type of operation not recorded in the cited sources) (CLM-0003)
- D 12 August 1988: Tuberculosis, diagnosed after admission to hospital and treated (CLM-0004)
- D November 2000: Raised PSA found on routine monitoring, followed by a prostate biopsy (CLM-0005)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Reach an informed, shared decision on treatment after hearing every reasonable option, including observation | 2001-04-14 | completed | Radiotherapy with six months of androgen deprivation chosen at the radiation oncology consultation |
| Complete six months of androgen deprivation and the course of radiotherapy with side effects managed | 2001-10-27 | completed | Two leuprolide depots and 37 fractions completed; testosterone castrate on treatment; mild hot flashes and urinary frequency, managed |
| Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise | 2001-07-14 | completed | Femoral neck T-score -1.4; vitamin D 34 ng/mL on supplementation; walking daily |
| PSA falling after radiotherapy, with a written surveillance plan | 2001-10-27 | completed | PSA 0.4 ng/mL six weeks after radiotherapy; PSA every six months planned |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Radiation oncology consultation to review staging and discuss curative treatment options and short-term androgen deprivation | completed | GL-AUA-ASTRO-PCA-2022-I, GL-NCCN-PROSTATE-2026 |
| Staging for unfavorable intermediate-risk disease with PSMA PET/CT | completed | GL-NCCN-PROSTATE-2026, GL-CMID-2026 |
| Treatment chosen through shared decision-making: image-guided external beam radiotherapy to the prostate with six months of androgen deprivation (leuprolide, with bicalutamide for the first four weeks) | completed | GL-AUA-ASTRO-PCA-2022-I, GL-AUA-ASTRO-PCA-2022-III, GL-NCCN-PROSTATE-2026 |
| Androgen deprivation monitoring: testosterone, PSA, blood pressure, glucose and lipids, DXA at baseline and every one to two years, vitamin D and calcium, hot flashes, mood, and cognition | completed | GL-CMID-2026, GL-ACS-PCA-SURV-2014 |
| After radiotherapy: PSA every six months for five years, then yearly, with recurrence defined as a rise of 2 ng/mL above the nadir (Phoenix); urinary and bowel symptoms at every visit | completed | GL-CMID-2026, GL-NCCN-PROSTATE-2026, GL-ACS-PCA-SURV-2014 |
| Distress screening at each visit, physical activity, and a written survivorship care plan | completed | GL-ACS-PCA-SURV-2014, GL-CMID-2026 |
Planned encounters
- 2001-03-10 — First visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral (ENC-001)
- 2001-04-14 — Five-week follow-up with radiation oncology consultation: staging result, shared decision on treatment, start of androgen deprivation, and bone density (ENC-002)
- 2001-06-09 — Subsequent annual wellness visit (ENC-005)
- 2001-07-14 — Three-month follow-up on androgen deprivation before radiotherapy: PSA, testosterone, vitamin D, and side effects (ENC-003)
- 2001-10-27 — Follow-up six weeks after radiotherapy: PSA, urinary and bowel effects, end of androgen deprivation, and the surveillance plan (ENC-004)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Annual Wellness Visit, Subsequent
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Focused Visit (Care-plan review)
- Radiation Oncology referral
- Radiation Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Annual Wellness Visit, Subsequent (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Focused Visit (Care-plan review) (XML)
- Radiation Oncology referral (XML)
- Radiation Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Biography of Nelson Mandela | Nelson Mandela Foundation | biography |
| SRC-0002 | Early prostate cancer is curable (archived copy) | Health24 | other |
| SRC-0003 | Former South African President Nelson Mandela diagnosed with prostate cancer (Associated Press) | News On 6 | other |
| SRC-0004 | Mandela begins radiation therapy | Irish Examiner | other |
| SRC-0005 | Mandela's prostate cancer not terminal, doctor says | The Globe and Mail | other |
| SRC-0006 | Mandela to continue radiation treatment | Mail & Guardian | other |
| SRC-0007 | Illnesses Madiba has suffered | SABC News | other |
| SRC-0008 | Nelson Mandela timeline 2000-2014 | South African History Online | other |
| SRC-0009 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the risk grouping, the choice of six months of androgen deprivation and conventional fractionation at 82, and the androgen deprivation monitoring. |
| provenance review | not_started | Recent-death rule: only what his doctors, his spokeswoman, his office, and he himself made public, with basic biographical facts from the Nelson Mandela Foundation. No statement or health fact is attributed to a relative or colleague. |
| safe messaging review | not_started | Imprisonment and tuberculosis are recorded as history only, factually; no behavioral-health diagnosis; death recorded without detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.